Vertex Stock Today

VRTX
 Stock
  

USD 287.32  5.23  1.79%   

Market Performance
6 of 100
Odds Of Distress
Less than 3
Vertex Pharmaceutic is trading at 287.32 as of the 27th of June 2022; that is -1.79% down since the beginning of the trading day. The stock's open price was 292.55. Vertex Pharmaceutic has a very small chance of experiencing financial distress in the next few years but had a somewhat modest performance during the last 90 days. Equity ratings for Vertex Pharmaceutic are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 28th of April 2022 and ending today, the 27th of June 2022. Click here to learn more.
CUSIP
92532F100
Fiscal Year End
December
Business Domain
Pharmaceuticals, Biotechnology & Life Sciences
IPO Date
24th of July 1991
Category
Healthcare
Classification
Health Care
ISIN
US92532F1003
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts. Vertex Pharmaceutic operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. The company has 254.25 M outstanding shares of which 3.41 M shares are at this time shorted by private and institutional investors with about 1.98 trading days to cover. More on Vertex Pharmaceutic
Follow Valuation Options Odds of Bankruptcy
Check how we calculate scores

Vertex Pharmaceutic Stock Highlights

Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. If you consider yourself one of those investors, make sure you clearly understand your entering position. Vertex Pharmaceutic's investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Vertex Pharmaceutic or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
Over 94.0% of the company outstanding shares are owned by institutional investors
Latest headline from stocknews.com: VRTX 3 Stocks Rated Strong-Buy For June 2022 - StockNews.com
ESG SustainabilitySome studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary, Vertex Pharmaceutic's sustainability indicators can be used to identify a proper investment strutegies using environmental, social, and governance scores that are crucial to Vertex Pharmaceutic's managers, analysts, and investors.
Environment Score
Governance Score
Social Score
ChairmanJoshua Boger
Thematic IdeaBiotech (view all)
Excise Tax ActivitiesAnimal TestingCatholic
Average Analyst Recommendation
Analysts covering Vertex Pharmaceutic report their recommendations after researching Vertex Pharmaceutic's financial statements, talking to executives and customers, or listening in on Vertex Pharmaceutic's conference calls. The current trade recommendation is based on an ongoing consensus estimate among financial analysts covering Vertex Pharmaceutic. The Vertex consensus assessment is calculated by taking the average forecast from all of the analysts covering Vertex Pharmaceutic.
Piotroski F Score
Piotroski F-Score is a popular financial indicator that puts together nine criteria to evaluate the financial strength of Vertex Pharmaceutic based on its profitability, leverage, liquidity, source of funds, and operating efficiency. It is an academic score (developed by Joseph Piotroski in 2002) to determine the current strength of Vertex Pharmaceutic financial position. Scores of 8 and 9 are usually classified as strong value stocks, whereas scores of 2 or below are considered weak value stocks.
 5 - HealthyDetails
Current ValueLast YearChange From Last Year 10 Year Trend
Weighted Average Shares235.3 M257.7 M
Significantly Down
Increasing
Slightly volatile
Weighted Average Shares Diluted237.3 M259.9 M
Significantly Down
Increasing
Slightly volatile
Net Cash Flow from Operations2.9 B2.6 B
Significantly Up
Increasing
Slightly volatile
Total Assets14.5 B13.4 B
Significantly Up
Increasing
Slightly volatile
Total Liabilities3.6 B3.3 B
Significantly Up
Increasing
Slightly volatile
Current Assets10.3 B9.6 B
Significantly Up
Increasing
Slightly volatile
Current Liabilities2.3 B2.1 B
Significantly Up
Increasing
Slightly volatile
Total Debt816.4 M756.7 M
Significantly Up
Increasing
Slightly volatile
Return on Average Assets20.0718.5997
Significantly Up
Increasing
Slightly volatile
Gross Margin97.9888.0624
Moderately Up
Decreasing
Stable
Asset Turnover0.540.6015
Moderately Down
Increasing
Slightly volatile
Macroaxis Advice
Unlike general analyst consensus, Macroaxis buy hold or sell recommendation is provided in the context of your current investment horizon and risk tolerance. The advice algorithm takes into account all of Vertex Pharmaceutic's available fundamental, technical, and predictive indicators. Your current horizon is 90 days - details
Strong BuyFairly Valued
Financial Strength
Vertex Pharmaceutic's financial strength is of vital concern to both outside investors and internal stakeholders. Efficiency and cost control are keys to Vertex Pharmaceutic's success, along with its ability to generate sufficient cash flow to pay bills, repay debt, and make a consistent year-to-year profit.
Financial leverage usually refers to the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Vertex Pharmaceutic's financial leverage. It provides some insight into what part of Vertex Pharmaceutic's total assets is financed by creditors.
Share Download
Share Download
By using current balance sheet information, investors can analyze the liability, assets, and equity on Vertex Pharmaceutic's books and decide whether to invest or hold. Statistics such as return on equity (ROE), debt to equity (D/E) help investors determine how Vertex Pharmaceutic deploys its capital and how much of that capital is borrowed.
Liquidity
Vertex Pharmaceutic cash flow analysis is essential to understand how it generates and spends money over a specific period. It can also help you figure out where your money is going and how much cash you have available at a given moment. The company currently holds 967.4 M in liabilities with Debt to Equity (D/E) ratio of 0.1, which may suggest the company is not taking enough advantage from borrowing. Vertex Pharmaceutic has a current ratio of 4.37, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist Vertex Pharmaceutic until it has trouble settling it off, either with new capital or with free cash flow. So, Vertex Pharmaceutic's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Vertex Pharmaceutic sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Vertex to invest in growth at high rates of return. When we think about Vertex Pharmaceutic's use of debt, we should always consider it together with cash and equity.

Operating Cash Flow

2.85 BillionShare
Vertex Pharmaceutic (VRTX) is traded on NASDAQ Exchange in USA and employs 3,900 people. The company currently falls under 'Large-Cap' category with current market capitalization of 74.38 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Vertex Pharmaceutic's market, we take the total number of its shares issued and multiply it by Vertex Pharmaceutic's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities. Vertex Pharmaceutic conducts business under Healthcare sector and is part of Biotechnology industry. The entity has 254.25 M outstanding shares of which 3.41 M shares are at this time shorted by private and institutional investors with about 1.98 trading days to cover. Vertex Pharmaceutic currently holds about 7.52 B in cash with 2.64 B of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 29.56.
Check Vertex Pharmaceutic Probability Of Bankruptcy
Ownership
Vertex Pharmaceutic shows a total of two hundred fifty-four million two hundred fifty thousand outstanding shares. The majority of Vertex Pharmaceutic outstanding shares are owned by institutional holders. These institutional investors are usually referred to as non-private investors looking to take positions in Vertex Pharmaceutic to benefit from reduced commissions. Consequently, institutions are subject to a different set of regulations than regular investors in Vertex Pharmaceutic. Please pay attention to any change in the institutional holdings of Vertex Pharmaceutic as this could imply that something significant has changed or about to change at the company. Please note that no matter how much assets the company owns, if the real value of the company is less than the current market value, you may not be able to make money on it.

Ownership Allocation (%)

Check Vertex Ownership Details

Vertex Stock Price Odds Analysis

What are Vertex Pharmaceutic's target price odds to finish over the current price? Based on a normal probability distribution, the odds of Vertex Pharmaceutic jumping above the current price in 90 days from now is nearly 4.68%. The Vertex Pharmaceutic probability density function shows the probability of Vertex Pharmaceutic stock to fall within a particular range of prices over 90 days. Given the investment horizon of 90 days Vertex Pharmaceutic has a beta of 0.9878. This entails Vertex Pharmaceutic market returns are sensitive to returns on the market. As the market goes up or down, Vertex Pharmaceutic is expected to follow. Additionally, the company has an alpha of 0.3939, implying that it can generate a 0.39 percent excess return over DOW after adjusting for the inherited market risk (beta).
  Odds Below 287.32HorizonTargetOdds Above 287.32
95.26%90 days
 287.32 
4.68%
Based on a normal probability distribution, the odds of Vertex Pharmaceutic to move above the current price in 90 days from now is nearly 4.68 (This Vertex Pharmaceutic probability density function shows the probability of Vertex Stock to fall within a particular range of prices over 90 days) .

Vertex Stock Institutional Holders

Institutional Holdings refers to the ownership stake in Vertex Pharmaceutic that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Vertex Pharmaceutic's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Vertex Pharmaceutic's value.
InstituionSecurity TypeTotal SharesValue
Blackrock IncCommon Shares23.9 M6.2 B
Vanguard Group IncCommon Shares20.5 M5.3 B
View Vertex Pharmaceutic Diagnostics

Vertex Pharmaceutic Historical Income Statement

Vertex Pharmaceutic Income Statement is one of the three primary financial statements used for reporting Vertex's overall financial performance over a current year or for a given accounting period. An Income Statement sometimes referred to as the statement of Vertex Pharmaceutic revenue and expense. Vertex Pharmaceutic Income Statement primarily focuses on the company's revenues and expenses during a particular period.
Vertex Pharmaceutic Selling General and Administrative Expense is fairly stable at the moment as compared to the past year. Vertex Pharmaceutic reported Selling General and Administrative Expense of 389.55 Million in 2021. Income Tax Expense is likely to rise to about 16.2 M in 2022, whereas Consolidated Income is likely to drop (104.3 M) in 2022. View More Fundamentals

Vertex Stock Against Markets

Picking the right benchmark for Vertex Pharmaceutic stock is fundamental to making educated investment choices. Many naive investors compare their positions with the S&P 500 or with the Nasdaq. But these benchmarks are not all-inclusive and generally should be used only for large-capitalization equities or stock offerings from large companies. When the price of a selected benchmark declines in a down market, there may be an uptick in Vertex Pharmaceutic stock price where buyers come in believing the asset is cheap. The opposite is true when the market is bullish; so, accurately picking the benchmark for Vertex Pharmaceutic is critical whether you are bullish or bearish towards Vertex Pharmaceutic at a given time.

Be your own money manager

Our tools can tell you how much better you can do entering a position in Vertex Pharmaceutic without increasing your portfolio risk or giving up expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate.risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Price Transformation Now

   

Price Transformation

Use Price Transformation models to analyze depth of different equity instruments across global markets
All  Next Launch Module

Vertex Pharmaceutic Corporate Directors

Vertex Pharmaceutic corporate directors refer to members of a Vertex Pharmaceutic board of directors. The board of directors generally takes responsibility for the Vertex Pharmaceutic's affairs and long-term direction of the entity. A corporate director does not make decisions for the corporation on his own. As a member of the board of directors, she or he must function as a part of a group that makes decisions on behalf of the business only by the board of directors' meetings. To pass a resolution, a majority of Vertex Pharmaceutic's board members must vote for the resolution. The Vertex Pharmaceutic board of directors' duties also include the election, removal, and supervision of officers, including the adoption, amendment, and repeal of bylaws.
William Young - Independent DirectorProfile
Alan Garber - Independent DirectorProfile
Margaret McGlynn - Independent DirectorProfile
Sangeeta Bhatia - DirectorProfile

Investing Vertex Pharmaceutic

You need to understand the risk of investing before taking a position in Vertex Pharmaceutic. The danger of trading Vertex Pharmaceutic is mainly related to its market volatility and company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Vertex Pharmaceutic is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Vertex Pharmaceutic. The Shape ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Vertex Pharmaceutic is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
Also, please take a look at World Market Map. Note that the Vertex Pharmaceutic information on this page should be used as a complementary analysis to other Vertex Pharmaceutic's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Risk-Return Analysis module to view associations between returns expected from investment and the risk you assume.

Complementary Tools for Vertex Stock analysis

When running Vertex Pharmaceutic price analysis, check to measure Vertex Pharmaceutic's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vertex Pharmaceutic is operating at the current time. Most of Vertex Pharmaceutic's value examination focuses on studying past and present price action to predict the probability of Vertex Pharmaceutic's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Vertex Pharmaceutic's price. Additionally, you may evaluate how the addition of Vertex Pharmaceutic to your portfolios can decrease your overall portfolio volatility.
Stock Screener
Find equities using custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook.
Go
Bond Directory
Find actively traded corporate debentures issued by US companies
Go
Watchlist Optimization
Optimize watchlists to build efficient portfolio or rebalance existing positions based on mean-variance optimization algorithm
Go
Equity Valuation
Check real value of public entities based on technical and fundamental data
Go
Portfolio Comparator
Compare the composition, asset allocations and performance of any two portfolios in your account
Go
Portfolio Holdings
Check your current holdings and cash postion to detemine if your portfolio needs rebalancing
Go
Bollinger Bands
Use Bollinger Bands indicator to analyze target price for a given investing horizon
Go
Portfolio Diagnostics
Use generated alerts and portfolio events aggregator to diagnose current holdings
Go
Idea Analyzer
Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas
Go
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
Go
Is Vertex Pharmaceutic's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Vertex Pharmaceutic. If investors know Vertex will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Vertex Pharmaceutic listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth YOY
0.19
Market Capitalization
74.8 B
Quarterly Revenue Growth YOY
0.22
Return On Assets
0.14
Return On Equity
0.25
The market value of Vertex Pharmaceutic is measured differently than its book value, which is the value of Vertex that is recorded on the company's balance sheet. Investors also form their own opinion of Vertex Pharmaceutic's value that differs from its market value or its book value, called intrinsic value, which is Vertex Pharmaceutic's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Vertex Pharmaceutic's market value can be influenced by many factors that don't directly affect Vertex Pharmaceutic's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Vertex Pharmaceutic's value and its price as these two are different measures arrived at by different means. Investors typically determine Vertex Pharmaceutic value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Vertex Pharmaceutic's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.